Literature, news and videos pertinent to
The Elena Siltanen
Pharmacy Advocacy Program

PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
By The ASCO Post Staff
December 10, 2023 - Supplement: ESMO Highlights

National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
By The ASCO Post Staff
October 10, 2022 - Supplement: Conference Highlights IASLC 2022

Screening for Lung Cancer with Low Dose Computed Tomography (LDCT)—CMS.gov Centers for Medicare & Medicaid Services

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT) —ClinicalTrials.gov

powered by Surfing Waves

The Elena Siltanen Pharmacy Advocacy Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.

For more information about this special program, please click on...

  1. Main
  2. About
  3. Photos
  4. Inspiration
  5. Tributes

Donate

We also accept PayPal
paypal.me/ICANadvocacy

Guidestar Platinum Seal of Transparency 2021

Federal Tax I.D.: EIN 86-0818253